Report cover image

Endometriosis Treatment Market, Opportunity, Growth Drivers, Industry Trend Analysis and Forecast, 2025-2034

Publisher Global Market Insights
Published Aug 11, 2025
Length 107 Pages
SKU # GMI20337000

Description

The Global Endometriosis Treatment Market was valued at USD 1.7 billion in 2024 and is estimated to grow at a CAGR of 13.1% to reach USD 5.6 billion by 2034.

The market growth is driven by rising awareness of women’s health, increasing diagnosis rates, and the introduction of advanced hormonal and non-hormonal therapies. Endometriosis, a chronic condition affecting reproductive health, has seen growing recognition as governments, healthcare providers, and advocacy groups emphasize the importance of early detection and effective treatment. The market’s expansion is further supported by investments in research for novel therapeutics and a growing pipeline of drugs aimed at improving patient outcomes with fewer side effects.

The market is segmented by drug type into oral contraceptives, gonadotropin-releasing hormone (GnRH) agonists and antagonists, progestins, non-steroidal anti-inflammatory drugs (NSAIDs), and others, with oral contraceptives leading the market in 2024, generating USD 432.5 million. Oral contraceptives are widely prescribed as a first-line treatment due to their cost-effectiveness, safety profile, and ability to manage pain while regulating menstrual cycles. With continuous innovations in formulation, including extended-cycle regimens and reduced hormonal dosages, these treatments are increasingly preferred by both patients and clinicians. Meanwhile, GnRH agonists and antagonists are expected to witness robust growth during the forecast period owing to their ability to provide longer-term relief, despite challenges related to bone density loss and cost.

In terms of distribution channel, hospital pharmacies accounted for the highest share in 2024, generating USD 866.4 million, as many endometriosis cases are diagnosed and managed in hospital settings, where specialists are available to prescribe advanced therapies. Hospitals also play a critical role in the administration of injectable treatments, surgical interventions, and follow-up care, making hospital pharmacies the dominant distribution hub. Retail pharmacies are also significant, driven by the high volume of oral contraceptive and NSAID prescriptions, while online pharmacies are gaining traction due to increasing consumer preference for convenience, privacy, and discounted pricing.

North America Endometriosis Treatment Market generated USD 714.8 million in 2024, fueled by higher diagnosis rates, increased healthcare spending, and strong adoption of innovative therapeutics. The presence of leading pharmaceutical companies and active support from advocacy groups such as the Endometriosis Association have further accelerated market growth. Europe follows closely, with rising awareness campaigns and favorable reimbursement policies contributing to strong demand. The Asia Pacific region is expected to grow the fastest during the forecast period, driven by increasing healthcare access in emerging markets such as India and China, along with growing awareness and rising government efforts to improve women’s health services.

Prominent companies in the market include AbbVie Inc., Bayer AG, Pfizer Inc., Teva Pharmaceutical Industries Ltd., Eli Lilly and Company, AstraZeneca plc, Novartis AG, Takeda Pharmaceutical Company Limited, Merck & Co., Inc., and Johnson & Johnson. The endometriosis treatment market is highly competitive, with leading players focusing on research and development, partnerships, and product innovations to maintain their market positions. Companies are increasingly investing in non-hormonal therapies and biologics, aiming to address unmet needs and minimize the long-term side effects associated with hormonal treatments. Strategic collaborations with healthcare providers, awareness campaigns, and patient support initiatives are also central to market strategies, ensuring greater accessibility and adherence to treatment plans. These players are working to expand their product portfolios with next-generation treatments, secure regulatory approvals, and enhance global distribution networks to strengthen their presence in the fast-growing endometriosis treatment market.

Table of Contents

107 Pages
Chapter 1 Methodology
1.1 Industry coverage
1.2 Market scope and definitions
1.3 Research design
1.4 Market size estimates and calculations
1.4.1 Approach 1: Data mining approach
1.4.2 Approach 2: Investor presentations
1.4.3 Approach 3: Parent market analysis
1.5 Key trends for market estimates
1.6 Forecast model
1.7 Primary research & validation
1.7.1 Primary sources
1.7.2 Data mining sources
1.7.2.1 Paid sources 19
1.7.2.2 Public sources
Chapter 2 Executive Summary
2.1 Industry 360 degree synopsis
2.1.1 Business trends
2.1.2 Regional trends
2.1.3 Disease type trends
2.1.4 Treatment type trends
2.1.5 Drug class trends
2.1.6 Route of administration trends
2.1.7 Distribution channel trends
Chapter 3 Industry Insights
3.1 Industry ecosystem analysis
3.2 Industry impact forces
3.2.1 Growth drivers
3.2.1.1 Rising prevalence and awareness of endometriosis
3.2.1.2 Advancement in diagnostic techniques
3.2.1.3 Increased government fundings and initiatives
3.2.2 Industry pitfalls and challenges
3.2.2.1 High cost of advanced treatment
3.3 Growth potential analysis
3.3.2 By treatment type
3.3.3 By drug class
3.3.4 By route of administration
3.3.5 By distribution channel
3.4 Regulatory landscape
3.4.1 U.S.
3.4.2 Europe
3.5 Pipeline analysis
3.6 Porter's analysis
3.7 PESTEL analysis
Chapter 4 Competitive Landscape
4.1 Introduction
4.1.1 AbbVie
4.1.2 Pfizer
4.1.3 AstraZeneca
4.2 Company matrix analysis
4.3 Competitive analysis of major market players
4.4 Competitive positioning matrix
4.5 Strategy dashboard
Chapter 5 Endometriosis Treatment Market, By Disease Type
5.1 Superficial peritoneal endometriosis
5.2 Ovarian endometriomas
5.3 Deep infiltrating endometriosis
5.4 Other disease types
Chapter 6 Endometriosis Treatment Market, By Treatment Type
6.1 Hormone therapy
6.2 Pain medication
Chapter 7 Endometriosis Treatment Market, By Drug Class
7.1 Gonadotropin releasing hormone
7.2 NSAIDs
7.3 Oral contraceptive
7.4 Other drug classes
Chapter 8 Endometriosis Treatment Market, By Route of Administration
8.1 Oral 65
8.2 Injectable
8.3 Other routes of administration
Chapter 9 Endometriosis Treatment Market, By Distribution Channel
9.1 Hospital pharmacies
9.2 Retail Pharmacies
9.3 Online Pharmacies
Chapter 10 Endometriosis Treatment Market, By Region
10.1 North America
10.2 Europe
10.3 Asia Pacific
10.4 Latin America
10.5 Middle East and Africa
Chapter 11 Company Profiles
11.1 AbbVie
11.1.1 Financial data
11.1.1.1 Sales revenue, 2021-2024 (USD Million)
11.1.2 Product landscape
11.1.3 Strategic outlook
11.1.4 SWOT analysis
11.2 AstraZeneca
11.2.1 Financial data
11.2.1.1 Sales revenue, 2021-2024 (USD Million)
11.2.2 Product landscape
11.2.3 SWOT analysis
11.3 Bayer 80
11.3.1 Financial data
11.3.1.1 Sales revenue, 2021-2024 (USD Million)
11.3.2 Product landscape
11.3.3 SWOT analysis
11.4 Debiopharm (Apres-demain SA)
11.4.1 Financial data
11.4.2 Product landscape
11.4.3 Strategic outlook
11.4.4 SWOT analysis
11.5 Gedeon Richter
11.5.1 Financial data
11.5.1.1 Sales revenue, 2021-2024 (USD Million)
11.5.2 Product landscape
11.5.3 Strategic outlook
11.5.4 SWOT analysis
11.6 Kissei Pharmaceuticals
11.6.1 Financial data
11.6.1.1 Sales revenue, 2020-2023 (USD Million)
11.6.2 Product landscape
11.6.3 Strategic outlook
11.6.4 SWOT analysis
11.7 Pfizer 94
11.7.1 Financial data
11.7.1.1 Sales revenue, 2021-2024 (USD Million)
11.7.2 Product landscape
11.7.4 SWOT analysis
11.9 Teva Pharmaceutical
11.9.1 Financial data
11.9.1.1 Sales revenue, 2021-2024 (USD Million)
11.9.2 Product landscape
11.9.3 SWOT analysis
11.10 Zydus 104
11.10.1 Financial data
11.10.1.1 Sales revenue, 2021-2024 (USD Million)
11.10.2 Product landscape
11.10.3 Strategic outlook
11.10.4 SWOT analysis

Search Inside Report

Pricing

Currency Rates
How Do Licenses Work?

How Do Licenses Work?

The primary function of a report license is to define how many people within a company are authorized to use the purchased report. This is separate to how a report might be delivered. Unless specifically identified otherwise, the purchase option is Single User. Below is a helpful description of that license, along with a sampling of others most commonly offered.

  • This license allows only one user to have access to and to use/read the report. It is not one user at a time or one user group; it is an individual who will be reading and utilizing the report.

  • This license allows for the entire purchasing company to read and use the report. This is the license level that would allow for a report to be placed on an internal company shared drive for access by all employees of that direct company. This license does not extend to parent or sister company use.

  • This license is designed to allow an entire department within a company full access to a report. The departmental license is a great option for companies that have more than one location and the department is spread out all over the country/world

  • This license is for companies that have one location where they want the report to be accessible by all employees within that physical location.

  • This is the most flexible of the licensing options. Some publishers will allow you to get a license for a preset number of people (typically 5). These licenses are ideal for small work groups.

License options are at the discretion of each publisher. As such, not all licenses indicated above are available for every product. If you are uncertain of the best license for your needs or would like a license that is not proactively available, please contact us and we will be happy to assist.

Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
Chat Now
Contact Us